

## Special Issue

# Influenza Virus and Vaccine Development

### Message from the Guest Editors

Influenza is a significant public health concern. Conventional vaccines (split, subviral or recombinant vaccines) mainly target viral hemagglutinin (HA) on the surface of viral particles and elicit neutralizing antibodies to prevent influenza infections. However, influenza viruses undergo frequent antigenic drift and/or antigenic shift that often compromise influenza vaccine performance or result in seasons with vaccine mismatch and poor protection. We are calling for manuscripts detailing the mechanisms of influenza virus replication and pathogenesis and describing how this information facilitates novel vaccine development. We particularly encourage submission of manuscripts that are not limited to HA but address other viral proteins (e.g., neuraminidase, matrix protein, polymerases) and/or different vaccine formats (e.g., DNA vaccine, viral-like particle). We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of influenza virus and vaccines.

---

### Guest Editors

Dr. Ewan Plant

Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA

Dr. Hang Xie

Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA

---

### Deadline for manuscript submissions

closed (31 December 2020)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/40962](https://mdpi.com/si/40962)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).